Equol and Regulation of Prostate Growth

雌马酚与前列腺生长的调节

基本信息

  • 批准号:
    7902005
  • 负责人:
  • 金额:
    $ 31.56万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2008
  • 资助国家:
    美国
  • 起止时间:
    2008-09-01 至 2012-07-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): This project will define the mechanism by which equol, an isoflavone metabolite, acts to inhibit normal and pathological growth of the prostate gland. In the United States, prostate cancer is the most frequently diagnosed cancer in men, and ranks second among cancer-related male deaths. The development of prostate cancer involves a complex interplay of numerous factors, however lifetime exposure to androgens, and advancing age, are two necessary etiological factors. Similarly, the development of benign prostatic hypertrophy (BPH) is also dependent upon androgen exposure and it is estimated that over half of the male population in the United States over the age of 60 have symptoms of BPH. The importance of androgen in prostate gland pathology is evidenced by current therapies for these diseases, which include reduction in circulating testosterone; inhibition of 5-alpha reductase, an enzyme that synthesizes the potent androgen, dihydrotestosterone; or blocking the actions of the androgen receptor. Diet is an important consideration when examining risk factors for hormone-dependent diseases such as prostate cancer. Asian men, on an eastern diet, have the lowest incidence of prostate cancer in the world. The basis for this correlation may be the presence of estrogen-like isoflavones (genistein and daidzein), in their diet. We have recently shown that equol, a product of isoflavone metabolism, has anti- androgenic properties as well. Equol selectively binds dihydrotestostserone and prevents androgen receptor activation to reduce androgen-dependent prostate growth. Equol is the principal metabolite of daidzein. It circulates at high levels, and is concentrated in the prostate. Moreover, equol can selectively bind estrogen receptor beta to activate an anti-proliferative cascade in prostate. Thus, equol possesses a unique dual action to inhibit prostate growth by 1) preventing proliferative actions of androgens, and 2) activating anti-proliferative actions of ERbeta. However, only about 30% of all humans have the correct intestinal flora to produce equol. In these studies, we will test the hypothesis that pathological growth of the prostate gland can be prevented or delayed by dietary equol. We will also determine the cellular mechanisms whereby equol provides such protection. These studies utilize the TRAMP mouse line where spontaneous prostate tumors develop in adult males making this particularly useful for studying the chemopreventive actions of equol. In addition, we will utilize an orthotopic injection model whereby human prostate carcinoma lines that express a luciferase reporter gene are injected into host mice and monitored by in vivo imaging techniques to determine the effects of equol, on growth of prostate tumors. Lastly, we will determine if equol can act by altering the polyamine biosynthetic pathway, thereby inhibiting cell cycle and tumor growth. PUBLIC HEALTH RELEVANCE: Prostate cancer is the most frequently diagnosed cancer in men, and ranks second among cancer-related male deaths in the United States. In this application, we will test the hypothesis that pathological growth of the prostate gland can be prevented or delayed by dietary administration of equol, a product of isoflavone metabolism that has anti-androgenic and estrogen receptor beta activating properties. The long-term goal of this project is to define the mechanism by which equol acts to inhibit the pathological growth of the prostate gland
描述(由申请人提供):该项目将定义雌马酚(一种异黄酮代谢物)抑制前列腺正常和病理性生长的机制。在美国,前列腺癌是男性中最常诊断出的癌症,在与癌症相关的男性死亡中排名第二。前列腺癌的发展涉及多种因素的复杂相互作用,然而终生暴露于雄激素和年龄增长是两个必要的病因因素。同样,良性前列腺肥大 (BPH) 的发展也取决于雄激素暴露,据估计,美国 60 岁以上的男性人口中有一半以上有 BPH 症状。目前针对这些疾病的治疗方法证明了雄激素在前列腺病理学中的重要性,其中包括减少循环睾酮;抑制 5-α 还原酶,一种合成强效雄激素二氢睾酮的酶;或阻断雄激素受体的作用。在检查前列腺癌等激素依赖性疾病的危险因素时,饮食是一个重要的考虑因素。采用东方饮食的亚洲男性前列腺癌发病率是世界上最低的。这种相关性的基础可能是他们的饮食中存在类雌激素异黄酮(金雀异黄酮和大豆黄酮)。我们最近表明,雌马酚是异黄酮代谢的产物,也具有抗雄激素特性。雌马酚选择性结合二氢睾酮并阻止雄激素受体激活,从而减少雄激素依赖性前列腺生长。雌马酚是大豆黄酮的主要代谢产物。它以高水平循环,并集中在前列腺中。此外,雌马酚可以选择性地结合雌激素受体β,激活前列腺中的抗增殖级联反应。因此,雌马酚具有独特的双重作用来抑制前列腺生长:1) 防止雄激素的增殖作用,2) 激活 ERbeta 的抗增殖作用。然而,只有约 30% 的人拥有产生雌马酚的正确肠道菌群。在这些研究中,我们将检验饮食雌马酚可以预防或延迟前列腺病理性生长的假设。我们还将确定牛尿酚提供此类保护的细胞机制。这些研究利用 TRAMP 小鼠品系,其中成年男性会出现自发性前列腺肿瘤,这对于研究雌马酚的化学预防作用特别有用。此外,我们将利用原位注射模型,将表达荧光素酶报告基因的人前列腺癌细胞系注射到宿主小鼠中,并通过体内成像技术进行监测,以确定雌马酚对前列腺肿瘤生长的影响。最后,我们将确定雌马酚是否可以通过改变多胺生物合成途径发挥作用,从而抑制细胞周期和肿瘤生长。公共卫生相关性:前列腺癌是男性中最常诊断出的癌症,在美国癌症相关男性死亡中排名第二。在本申请中,我们将测试这样的假设:通过饮食给予雌马酚可以预防或延迟前列腺的病理性生长,雌马酚是异黄酮代谢的产物,具有抗雄激素和雌激素受体β激活特性。该项目的长期目标是明确雌马酚抑制前列腺病理生长的机制

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Robert J Handa其他文献

Robert J Handa的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Robert J Handa', 18)}}的其他基金

Sex differences in fetal programming by glucocorticoids: Adult hypothalamus and Autonomic Nervous System
糖皮质激素对胎儿编程的性别差异:成人下丘脑和自主神经系统
  • 批准号:
    10540810
  • 财政年份:
    2020
  • 资助金额:
    $ 31.56万
  • 项目类别:
Sex differences in fetal programming by glucocorticoids: Adult hypothalamus and Autonomic Nervous System
糖皮质激素对胎儿编程的性别差异:成人下丘脑和自主神经系统
  • 批准号:
    10089495
  • 财政年份:
    2020
  • 资助金额:
    $ 31.56万
  • 项目类别:
Sex differences in fetal programming by glucocorticoids: Adult hypothalamus and Autonomic Nervous System
糖皮质激素对胎儿编程的性别差异:成人下丘脑和自主神经系统
  • 批准号:
    10349465
  • 财政年份:
    2020
  • 资助金额:
    $ 31.56万
  • 项目类别:
Estrogen Regulation of the Hypothalamo-Pituitary-Adrenal Axis
雌激素对下丘脑-垂体-肾上腺轴的调节
  • 批准号:
    9043875
  • 财政年份:
    2015
  • 资助金额:
    $ 31.56万
  • 项目类别:
Estrogen Regulation of the Hypothalamo-Pituitary-Adrenal Axis
雌激素对下丘脑-垂体-肾上腺轴的调节
  • 批准号:
    9040279
  • 财政年份:
    2015
  • 资助金额:
    $ 31.56万
  • 项目类别:
Gonadal Steroid Receptors and the Hypothalamo-Pituitary-Adrenal Axis
性腺类固醇受体和下丘脑-垂体-肾上腺轴
  • 批准号:
    7816043
  • 财政年份:
    2009
  • 资助金额:
    $ 31.56万
  • 项目类别:
Gonadal Steroid Receptors and the Hypothalamo-Pituitary-Adrenal Axis
性腺类固醇受体和下丘脑-垂体-肾上腺轴
  • 批准号:
    8401542
  • 财政年份:
    2009
  • 资助金额:
    $ 31.56万
  • 项目类别:
Gonadal Steroid Receptors and the Hypothalamo-Pituitary-Adrenal Axis
性腺类固醇受体和下丘脑-垂体-肾上腺轴
  • 批准号:
    8013781
  • 财政年份:
    2009
  • 资助金额:
    $ 31.56万
  • 项目类别:
Gonadal Steroid Receptors and the Hypothalamo-Pituitary-Adrenal Axis
性腺类固醇受体和下丘脑-垂体-肾上腺轴
  • 批准号:
    7760577
  • 财政年份:
    2009
  • 资助金额:
    $ 31.56万
  • 项目类别:
Gonadal Steroid Receptors and the Hypothalamo-Pituitary-Adrenal Axis
性腺类固醇受体和下丘脑-垂体-肾上腺轴
  • 批准号:
    8206764
  • 财政年份:
    2009
  • 资助金额:
    $ 31.56万
  • 项目类别:

相似国自然基金

S-腺苷甲硫氨酸脱羧酶1介导的多胺调控ODV RepA诱导HR的分子机制研究
  • 批准号:
    31671997
  • 批准年份:
    2016
  • 资助金额:
    65.0 万元
  • 项目类别:
    面上项目
SAMDC调控多胺参与棉花抗逆分子机制研究
  • 批准号:
    31301363
  • 批准年份:
    2013
  • 资助金额:
    21.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Characterization of polyamine biosynthetic enzymes from human gut microbes associated with colon and pancreatic cancer
与结肠癌和胰腺癌相关的人类肠道微生物的多胺生物合成酶的表征
  • 批准号:
    10664019
  • 财政年份:
    2022
  • 资助金额:
    $ 31.56万
  • 项目类别:
Characterization of polyamine biosynthetic enzymes from human gut microbes associated with colon and pancreatic cancer
与结肠癌和胰腺癌相关的人类肠道微生物的多胺生物合成酶的表征
  • 批准号:
    10664019
  • 财政年份:
    2022
  • 资助金额:
    $ 31.56万
  • 项目类别:
Nicotinamide N-methyltransferase is a novel regulator of energy expenditure
烟酰胺 N-甲基转移酶是一种新型的能量消耗调节剂
  • 批准号:
    9212132
  • 财政年份:
    2014
  • 资助金额:
    $ 31.56万
  • 项目类别:
Nicotinamide N-methyltransferase is a novel regulator of energy expenditure
烟酰胺 N-甲基转移酶是一种新型能量消耗调节剂
  • 批准号:
    8610487
  • 财政年份:
    2014
  • 资助金额:
    $ 31.56万
  • 项目类别:
Validating novel drug targets in Trypanosoma cruzi polyamine biosynthesis
验证克氏锥虫多胺生物合成中的新药物靶点
  • 批准号:
    8525512
  • 财政年份:
    2013
  • 资助金额:
    $ 31.56万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了